Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (55)

I-02Chayan Acharya

Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia

Wednesday 10:00-11:30

I-11Marcus Baaz

Model-based Prediction of Progression-Free Survival for Combination Therapies in Oncology

Wednesday 10:00-11:30

I-12Annabelle Ballesta

Quantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors.

Wednesday 10:00-11:30

I-14Imke Bartelink

Physiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer

Wednesday 10:00-11:30

I-16Maxime Beaulieu

Simulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer

Wednesday 10:00-11:30

I-20Elisa Borella

Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients

Wednesday 10:00-11:30

I-21Muriel Boulton

Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer

Wednesday 10:00-11:30

I-23Aurore CARROT

Prognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study

Wednesday 10:00-11:30

I-24Marc Cerou

Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials

Wednesday 10:00-11:30

I-28Siak-Leng CHOI

Applying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC)

Wednesday 10:00-11:30

I-29John Clements

Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy

Wednesday 10:00-11:30

I-38Xiaoqing Fan

Pharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia

Wednesday 10:00-11:30

I-40Fernandez Teruel Carlos

Exposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant

Wednesday 10:00-11:30

I-44Glenn Gauderat

Mechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data

Wednesday 10:00-11:30

I-46Eva Germovsek

A semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus

Wednesday 10:00-11:30

I-48Daniel Glazar

A simulation-based sample size analysis of a joint model of longitudinal and survival data for patients with glioma

Wednesday 10:00-11:30

I-49Xiaohua Gong

Pharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements

Wednesday 10:00-11:30

I-50Sebastiaan Goulooze

Conditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making

Wednesday 10:00-11:30

I-52Jinju Guk

Integration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling.

Wednesday 10:00-11:30

I-56Jennifer Hibma

Population Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma

Wednesday 10:00-11:30

I-59Itziar Irurzun Arana

Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer

Wednesday 10:00-11:30

I-67Huub Jan Kleijn

Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers

Wednesday 10:00-11:30

I-68Fenja Klima

Separating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data

Wednesday 10:00-11:30

I-88Elena Tosca

Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach

Wednesday 10:00-11:30

I-89Mira Tout

A translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues

Wednesday 10:00-11:30

I-91Lisa van der Heijden

Quantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours

Wednesday 10:00-11:30

I-95Anyue Yin

Population pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma

Wednesday 10:00-11:30

I-96Seok Kyue Yoon

Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer

Wednesday 10:00-11:30

III-10Summer Feng

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin

Thursday 10:15-11:45

III-25Marie Lambert

Population pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration

Thursday 10:15-11:45

III-28Félicien Le Louedec

Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients

Thursday 10:15-11:45

III-29Félicien Le Louedec

Model-informed precision dosing of protein kinase inhibitors: benefits and limits. The example of imatinib.

Thursday 10:15-11:45

III-32Apolline Lefevre

A mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies

Thursday 10:15-11:45

III-39Sarah Lobet

Influence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab

Thursday 10:15-11:45

III-41Aurelie Lombard

Exploring the use of constant and time-varying observation-based versus model-based tumour size metrics for early predictions of drug efficacy on overall survival in malignant pleural mesothelioma

Thursday 10:15-11:45

III-43Vincent Madelain

Impact of interaction model choice in PKPD analysis evaluating drug combination in TGI in vivo studies

Thursday 10:15-11:45

III-52Mourad Mseddi

Population pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer

Thursday 10:15-11:45

III-53Ida Neldemo

Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study

Thursday 10:15-11:45

III-58Theodoros Papathanasiou

Population pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment

Thursday 10:15-11:45

III-60Antoine Pitoy

Contribution of modelling jointly progression-free survival and biomarker longitudinal data for therapeutic evaluation in oncology

Thursday 10:15-11:45

III-62Alicja Puszkiel

Nivolumab de-escalation in patients with complete response: model-based simulations of alternative dosing regimens and noninferiority clinical trials

Thursday 10:15-11:45

III-65Pascale Rietveld

Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin

Thursday 10:15-11:45

III-66Maša Roganović

Modelling fatigue events in prostate cancer patients on radiotherapy

Thursday 10:15-11:45

III-67Davide Ronchi

Model-based analysis of patient-derived organoids for evaluating anticancer drugs

Thursday 10:15-11:45

III-68Alberto Russu

Population pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer

Thursday 10:15-11:45

III-71Javier Sanchez Fernandez

Building evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example

Thursday 10:15-11:45

III-72Aymara Sancho

Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: the interplay between cancer cells and components of the tumor microenvironment.

Thursday 10:15-11:45

III-75Emilie Schindler

Population PK-PD modeling and exposure-response analysis in multiple myeloma patients treated with intravenous forimtamig, a T-cell engaging 2:1 bispecific antibody targeting GPRC5D and CD3

Thursday 10:15-11:45

III-76Miriam Schirru

A QSP model for predicting efficacy assessment of combined treatment of radiotherapy and anti-PD-1 for NSCLC patients through virtual clinical trials.

Thursday 10:15-11:45

III-77Alejandro Serrano Alcaide

Application of an immune-oncology framework to explore the role of regulatory T cells in antitumor response.

Thursday 10:15-11:45

III-79Hinke Huisman-Siebinga

Optimizing radionuclide therapy with 177Lu-HA-DOTATATE in patients with neuroendocrine tumors using semi-physiological population PK models

Thursday 10:15-11:45

III-82Tomas Sou

Population PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies

Thursday 10:15-11:45

III-84Herbert Struemper

Development of a joint tumor size (TS)–overall survival (OS) modelling and simulation (M&S) framework supporting oncology development decision making

Thursday 10:15-11:45

III-86Zhiyuan Tan

Population pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma

Thursday 10:15-11:45

III-87David Ternant

A multi drug disposition model accounting for rituximab antigen binding portion (Fab) and crystallizable (Fc) mediated drug disposition mechanisms

Thursday 10:15-11:45